DavidRGreeleyMDFAAN

PubMed

• Naturalistic assessment of everyday multitasking in Parkinson's disease with and without mild cognitive impairment.
  Maureen Schmitter-Edgecombe, Katelyn Brown, Reanne Cunningham Chilton, Nicole Whiteley, David Greeley> ;The Clinical Neuropsychologist. 2024 Mar 12
• ALSUntangled #66: antimycobacterial antibiotics.
  Ellen S Pierce, Paul Barkhaus, Morgan Beauchamp, Mark Bromberg, Gregory T Carter, Jill Goslinga, David Greeley, Sky Kihuwa-Mani, Gleb Levitsky, Isaac Lund, Christopher...> ;Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2023 Aug 1
• 1 citations
  A Comparison of Functional Abilities in Individuals with Mild Cognitive Impairment and Parkinson's Disease with Mild Cognitive Impairment Using Multiple Assessment Met...
  Maureen Schmitter-Edgecombe, Courtney McAlister, David R. Greeley> ;Journal of the International Neuropsychological Society. 2021 Sep 6
• 2 citations
  A Retrospective Cost Analysis of Patients Who Switched from OnabotulinumtoxinA to IncobotulinumtoxinA in a Private Neurology Practice
  Victoria K Karschney, David R. Greeley> ;American Health & Drug Benefits. 2020 Nov 30
• 55 citations
  The sensitivity and specificity of the 9-item Wearing-off Questionnaire
  Mark Stacy, J.M. Murphy, David R. Greeley, R.M. Stewart, H. Murck, X. Meng> ;Parkinsonism & Related Disorders. 2008 Apr 1
• 14 citations
  Prospective Study Evaluating IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm: Interim Results from the First 145 Subjects with Cervical Dystonia
  Hubert H. Fernandez, Fernando Pagan, Fabio Danisi, David R. Greeley, Joseph Jankovic, Amit Verma, Kapil D. Sethi, Eric J. Pappert> ;Tremor and Other Hyperkinetic Movements. 2013 May 16
• 3 citations
  Gamma knife radiosurgery for movement disorders: a concise review of the literature
  Ameer L. Elaimy, Benjamin J. Arthurs, Wayne T. Lamoreaux, John J. Demakas, Alexander R. Mackay, Robert K. Fairbanks, David R. Greeley, Barton S. Cooke, Christopher M. Lee> ;World Journal of Surgical Oncology. 2010 Jul 21
• 14 citations
  Gamma knife radiosurgery for essential tremor: A Case report and review of the literature
  Ameer L. Elaimy, John J. Demakas, Benjamin J. Arthurs, Barton S. Cooke, Robert K. Fairbanks, Wayne T. Lamoreaux, Alexander R. Mackay, David R. Greeley, Christopher M. Lee> ;World Journal of Surgical Oncology. 2010 Mar 22
• 84 citations
  Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
  Hubert H. Fernandez, David R. Greeley, Richard M. Zweig, Joanne Wojcieszek, A Mori, Neil M. Sussman> ;Parkinsonism & Related Disorders. 2010 Jan 1
• 171 citations
  Characterizing multiple memory deficits and their relation to everyday functioning in individuals with mild cognitive impairment.
  Maureen Schmitter-Edgecombe, Ellen Woo, David R. Greeley> ;Neuropsychology. 2009 Mar 1
• Join now to see all

Other

• Current Therapeutic Approaches to the Treatment of Parkinson’s disease. 
  Demos R, Setter SM, Greeley DR, Johnson K, Washington Pharmacy
• Neuroimmunophilin Ligands: A Novel Treatment for Parkinson’s disease. 
  Harrell J, Setter SM, Greeley DR, Consult Pharm
• Potential Advances in the Treatment of Parkinson’s Disease. 
  Setter SM, Iltz JL, Greeley DR, Advances in Pharmacy
• Normal Pressure Hydrocephalus. 
  Neumiller JJ, Neumiller JJ, Gates BJ, Setter SM, Greeley DR
  http://www.uspharmacist.com/content/t/neurology/c/10438/
• Review of HIV-Associated Dementia (HIV-D). 
  Thams J, Setter SM, Terriff C, Greeley DR, Advances in Pharmacy
• Dementia with Lewy Bodies. 
  Sonnett T, Setter SM, Greeley DR, U.S. Pharmacist
• The Sensitivity and Specificity of the 9-item Wearing-off Questionnaire. 
  Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X, Parkinsonism Relat Disord
• Clopidogrel (Plavix®) vs. Aspirin in Patients with RIND or TIA. 
  Bristol-Myers Squibb
• Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of a Second Sumatriptan (Imitrex®) Tablet in the Acute Treatment of Migraine Subjects. 
  Glaxo Wellcome
• A Phase II/III Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability. 
  Boehringer Ingelheim/Cambridge Neuroscience
  http://jama.highwire.org/cgi/content/abstract/286/21/2673
• A Multicenter, Double-Blind, Placebo-Controlled, Parallel, Graduated-Dose Clinical Trial of Botulinum Toxin, Type A (Botox®) for the Treatment of Chronic Low Back Mus... 
  Allergan
• A Four Month, Double-Blind, Dose-Controlled, Parallel Group, Multicenter Study to Determine the Efficacy and Safety of Gabapentin (Neurontin®) in Newly Diagnosed Pati... 
  Parke-Davis
• A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Alniditan Given Subcutaneous in Acute Treatment of Migraine. 
  Janssen
• An Open Evaluation of the Long-Term Efficacy, Safety and Tolerability of Alniditan Subcutaneous in the Acute Treatment of Migraine Attacks. 
  Janssen
• An Open-Label Study to Evaluate the Safety and Efficacy of Rivastigmine (Exelon®) in Patients with Mild to Severe Probable Alzheimer’s Disease in the Community Setting. 
  Novartis
• A Randomized, Double-Blind, Double-Dummy, Active/Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan (Amerge®) Compared to Oral Sumatriptan (Imitrex®). 
  Glaxo Wellcome
• JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri. 
  Biogen Idec Inc: Stratify 2, Protocol Number 101JC402
• A Phase IV, Prospective, Observational Trial Evaluating Xeomin (Incobotulinumtoxin A) for Cervical Dystonia or Blepharospasm in the United States. 
  Merz, Protocol Number MRZ
• A Prospective, Multi-Center, Randomized, Open-Label Study with Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Entacapone (Comtan®). 
  Novartis
• A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine (Lidoderm®) Patch 5% with Placebo in Patients with Pain From Carpal Tunnel Syndrome. 
  Endo
• An Open-Label, Multicenter, Study of the Continued Safety of Istradefylline in Subjects With Parkinson’s Disease Who Have Recently Completed One Year of Treatment Wit... 
  Kyowa
• A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole CR (ReQuip®) in Patients with Restless Legs Syndrome. 
  GlaxoSmithKline
• A 16-week, Randomized, Double-blind, Placebo and Pregabalin (Lyrica®) Controlled, Multi-center Trial of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia. 
  Pfizer
• An open label extension trial assessing the safety and tolerability of [S,S]-Reboxetine in patients with Postherpetic Neuralgia. 
  Pfizer
• A prospective, double-blind, placebo-controlled, randomized, multi-center trial with a double-blind parallel-group extension period to investigate the efficacy. 
  Merz
• Join now to see all